|1.||Separovic, Duska: 5 articles (05/2015 - 01/2013)|
|2.||Baron, Elma D: 5 articles (06/2014 - 05/2008)|
|3.||Oleinick, Nancy L: 5 articles (08/2012 - 01/2010)|
|4.||Ahmad, N: 5 articles (05/2001 - 11/2000)|
|5.||Mukhtar, H: 5 articles (05/2001 - 11/2000)|
|6.||Korbelik, Mladen: 4 articles (05/2015 - 09/2013)|
|7.||Bielawski, Jacek: 4 articles (05/2015 - 01/2013)|
|8.||Bielawska, Alicja: 4 articles (05/2015 - 09/2013)|
|9.||Cooper, Kevin D: 4 articles (06/2014 - 01/2010)|
|10.||Stochaj, Ursula: 3 articles (05/2015 - 11/2014)|
03/01/2008 - "Using silicon phthalocyanine 4 (Pc4) as photosensitizer, nontumor-bearing CD4 knockout (CD4-/-) mice and their wild type (WT) counterparts were subjected to Pc4-PDT in a manner identical to that used for tumor regression (1 cm spot size, 0.5 mg kg(-1) Pc4, 110 J cm(-2) light) to assess the effect of Pc4-PDT on cell-mediated immunity. "
09/01/1993 - "Twenty-four hours following the intraperitoneal administration of AlPcTS or SiPc IV to tumor-bearing animals, the tumor to normal skin ratio of the photosensitizer was 1.6 or 1.5, respectively. "
08/06/2012 - "Optimization of a nanomedicine-based silicon phthalocyanine 4 photodynamic therapy (Pc 4-PDT) strategy for targeted treatment of EGFR-overexpressing cancers."
01/01/2011 - "Preliminary clinical and pharmacologic investigation of photodynamic therapy with the silicon phthalocyanine photosensitizer pc 4 for primary or metastatic cutaneous cancers."
12/01/2010 - "Silicon phthalocyanine (Pc 4) photodynamic therapy is a safe modality for cutaneous neoplasms: results of a phase 1 clinical trial."
|2.||Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)
|3.||Melanoma (Melanoma, Malignant)
03/01/1999 - "Vesicular stomatitis virus (VSV) was used as a model virus to study the processes involved in photoinactivation by aluminum phthalocyanine tetrasulfonate (AlPcS4) or silicon phthalocyanine HOSiPcOSi(CH3)2(CH2)3N(CH3)2 (Pc4) and red light. "
03/01/1997 - "Vesicular stomatitis virus (VSV) was used as a model virus to study the primary targets of photoinactivation by aluminum phthalocyanine tetrasulfonate (AIPcS4) or silicon phthalocyanine HOSiPcOSi(CH3)2(CH2)3N(CH3)2 (Pc4) and red light. "
|5.||Squamous Cell Carcinoma (Epidermoid Carcinoma)
06/09/1998 - "We investigated the involvement of cell cycle regulatory events during silicon phthalocyanine (Pc4)-PDT-mediated apoptosis in human epidermoid carcinoma cells A431. "
07/01/1995 - "Intradermally injected human squamous cell carcinoma cells were grown to 40 to 80 mm3 in athymic nude mice and irradiated with 675-nm light (75 J/cm2, 75 mW/cm2) 24 hours after the intraperitoneal injection of SiPc IV (1.0 mg/kg). "
02/01/2015 - "PDT with Pc4, a silicon phthalocyanine photosensitizer, was combined with C6-pyridinium ceramide (LCL29) to determine their potential to promote death of SCC17B human head and neck squamous cell carcinoma cells. "
11/01/2014 - "We used the silicon phthalocyanine Pc4 for PDT, and SCC17B cells, as a clinically-relevant model of human head and neck squamous carcinoma. "
04/26/2001 - "We earlier showed an involvement of: (i) WAF1/p21-cyclins (D1 and E)-cdk (2 and 6) network; and (ii) Rb/E2F-DP machinery during silicon phthalocyanine (Pc4)-PDT-mediated cell cycle dysregulation and apoptosis of human epidermoid carcinoma (A431) cells. "
|2.||Photosensitizing Agents (Photosensitizers)
|5.||Cytochromes c (Cytochrome c)
|6.||CD95 Antigens (fas Receptor)
|9.||Small Interfering RNA (siRNA)
|10.||Cyclin-Dependent Kinases (cdk Proteins)
|1.||Photochemotherapy (Photodynamic Therapy)